ImmunityBio(US:IBRX) Seeking Alpha·2026-02-18 10:12分组1 - ImmunityBio, Inc. (IBRX) stock is experiencing a bullish trend driven by investor confidence in its chemo-free immunotherapy platform led by Anktiva, an IL-15 superagonist [1] - The company focuses on innovative biotechnology solutions, emphasizing unique mechanisms of action and first-in-class therapies that have the potential to reshape treatment paradigms [1] - The analysis aims to evaluate the science behind drug candidates, the competitive landscape, clinical trial design, and market opportunities while balancing financial fundamentals and valuation [1] 分组2 - The author has a background in Cell Biology and experience in drug discovery, which informs their investment analysis in the biotech sector [1] - The intention is to provide insights that help investors understand both opportunities and risks in the rapidly evolving biotech industry [1]